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Ángel Alonso3, Jose Luis Soto2,8, Megan Hitchins9, Marta Pineda1 and Gabriel Capellá1
BACKGROUND: Constitutional MLH1 epimutations are characterised by monoallelic methylation of the MLH1 promoter throughout
normal tissues, accompanied by allele-specific silencing. The mechanism underlying primary MLH1 epimutations is currently
unknown. The aim of this study was to perform an in-depth characterisation of constitutional MLH1 epimutations targeting the
aberrantly methylated region around MLH1 and other genomic loci.
METHODS: Twelve MLH1 epimutation carriers, 61 Lynch syndrome patients, and 41 healthy controls, were analysed by Infinium
450 K array. Targeted molecular techniques were used to characterise the MLH1 epimutation carriers and their inheritance pattern.
RESULTS: No nucleotide or structural variants were identified in-cis on the epimutated allele in 10 carriers, in which inter-
generational methylation erasure was demonstrated in two, suggesting primary type of epimutation. CNVs outside the MLH1 locus
were found in two cases. EPM2AIP1-MLH1 CpG island was identified as the sole differentially methylated region in MLH1
epimutation carriers compared to controls.
CONCLUSION: Primary constitutional MLH1 epimutations arise as a focal epigenetic event at the EPM2AIP1-MLH1 CpG island in the
absence of cis-acting genetic variants. Further molecular characterisation is needed to elucidate the mechanistic basis of MLH1
epimutations and their heritability/reversibility.
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INTRODUCTION
Lynch syndrome (LS) is characterised by an increased risk for
colorectal cancer (CRC) and cancers of the endometrium, ovary,
stomach, small intestine, hepatobiliary tract, urinary tract, brain,
and skin1. LS is caused by a germline genetic variant within a
mismatch repair (MMR) gene, MLH1 (MutL homolog 1), MSH2 (MutS
Homolog 2), MSH6 (MutS homolog 6) or PSM2 (PMS1 Homolog 2), or
a terminal deletion of EPCAM (Epithelial Cell Adhesion Molecule
gene) with consequent epigenetic inactivation of MSH2. In a small
proportion of LS patients the cancer predisposition is caused by a
constitutional epimutation of MLH1, in which one allele of the CpG
island promoter is aberrantly hypermethylated throughout normal
tissues with associated loss-of-expression from this allele2.
Two types of constitutional MLH1 epimutation have been
defined: secondary, which are linked in-cis to a genetic alteration
and follow an autosomal dominant pattern of inheritance3–10; and
primary, which occur in the absence of any apparent linked
sequence change, typically arise de novo6,11–16, and demonstrate
null6,11,13,17 or non-Mendelian inheritance9,11,18. To date, 75 index
cases with a constitutional MLH1 epimutation have been
reported19,20, accounting for 2–3% of mutation negative cases
with suspected LS whose tumors are MLH1-deficient21. Most of
these (66/75) have been considered primary19,20. The available
evidence from these cases suggests that constitutional MLH1
epimutations cause a severe LS phenotype, including a young age
of cancer onset and multiple primary tumors.
Previous studies on constitutional MLH1 epimutation have
focused on the role of this molecular defect in cancer causation
by confirming the presence of MLH1 promoter methylation and
corresponding transcriptional silencing within normal tissues,
refining the selection criteria for patients warranting screening for
it, and the inheritance patterns within families. It has been proposed
that primary MLH1 epimutations arise in the germline or early stages
of embryonic development, since they are monoallelic and soma-
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wide, but frequently exhibit mosaic methylation and expression
loss2. However, no comprehensive studies have been undertaken to
elucidate the mechanism(s) underlying primary MLH1 epimutations,
such as whether they are localized within the MLH1 locus due to a
focal defect, or if additional genes are concomitantly affected due to
widespread epigenetic perturbation. The main aim of our study was
to perform an in-depth characterisation of the methylation profile in
cases with a confirmed constitutional MLH1 epimutation to define
the extent of the aberrantly methylated region around MLH1, as well
as other loci on a genome-wide scale. The results from this study
contribute to the understanding of primary constitutional MLH1




Twelve Caucasian MLH1 epimutation carriers were recruited from
the west Mediterranean area, among which eight were previously
reported13,22,23. The four new cases were referred from Complejo
Hospitalario de Navarra and Doce de Octubre University Hospital
due to the identification of MLH1methylation in blood by MS-MLPA.
The original numerical code for each proband was maintained from
previous publications; however, a prefix corresponding to the
referral center (below) was added (Table S1). Clinico-pathological
data collected included age at cancer diagnosis, tumor location,
immunohistochemistry of MMR proteins in tumors, and MLH1
methylation status in tumor and blood DNA (Table S1). Forty-one
healthy controls (selected to appropriately match the patients by
age, race, and geographic location), 61 LS patients with confirmed
genetic mutations (21 MLH1, 28 MSH2, 9 MSH6, 3 PMS2), and four
CRC patients whose tumors demonstrated somatic MLH1-methyla-
tion, were included as controls (Table S2). Written informed consent
was obtained from all individuals, and the ethics committee of the
respective hospitals approved the study.
Samples of peripheral blood leukocytes (PBL) DNA were
collected from biobanks at the Catalan Institute of Oncology
(ICO), Elche University Hospital (HGUE), Valencian Biobank Net-
work (IBSP-CV), Complejo Hospitalario de Navarra (CHN), Doce de
Octubre University Hospital (H12O), and Policlinico S.Orsola-
Malpighi (M). Lymphoblastoid cell lines were established from
the B lymphocytes of MLH1 epimutation carriers by standard EBV-
transformation using supernatant from the B95.5 cell lines, as
described in Supplementary Methods. Colorectal tumors and
distal normal mucosa were collected as formalin-fixed paraffin
embedded (FFPE) tissues when available (Table S2).
For each FFPE specimen, 10–20 × 10-μm sections were cut from
a single-representative block per case, using macrodissection with
a scalpel if needed to enrich for tumor cells. After deparaffinization
using Deparaffinization Solution (Qiagen, Hilden, Germany), DNA
was isolated using the QIAmp DNA FFPE Tissue Kit (Qiagen)
according to the manufacturer’s instructions.
Methylation analyses
The initial detection or confirmation of the presence of MLH1
methylation in each proband and consenting family members was
performed by methylation-specific multiplex ligation-dependent
probe amplification (MS-MLPA) on genomic DNA from PBL. For all
other methylation analyses, DNA was subject to sodium bisulphite
modification using the EZ DNA Methylation Kit (Zymo Research),
according to the manufacturer’s instructions.
MS-MLPA. The presence of methylation at the MLH1 promoter
was detected and confirmed using 100 ng of PBL DNA using the
SALSA MLPA ME011 Mismatch Repair genes probemix (MRC-
Holland), according to the manufacturer’s instructions. DNA from
the RKO CRC cell line was used as the MLH1 methylation-positive
control. The amplification products were run on an ABI Prism 3130
DNA sequencer and analysed using GeneMapper v4.0 (Applied
Biosystems).
Clonal bisulfite sequencing. Clonal bisulfite sequencing of frag-
ments of the MLH1 promoter was used to determine the allelic
methylation profile in bisulfite modified PBL DNA from MLH1
epimutation carriers who were found to be heterozygous for a
promoter variant. Primers were used to amplify specific promoter
regions encompassing each promoter variant (Table S3), and PCR
products were cloned in E. coli cells using the TOPO TA cloning kit
(Invitrogen) to separate the amplicons into individual alleles. The
inserts from at least 24 individual colonies were sequenced using
plasmid vector primers. Additional methodological details are
provided in Supplementary Methods. The methylation status at
individual CpG site and the allele of each heterozygous variant
within each promoter fragment was determined using SeqMan
software (DNASTAR) or Mutation Surveyor (SoftGenetics).
Methylation array analysis. PBL DNA samples (1000 ng) from
patients and controls, and 500–1000 ng of available FFPE color-
ectal cancer DNA and distal normal colon tissue DNA, were
randomized within 96-well plates. For internal quality control,
in vitro methylated and unmethylated DNAs were included in
each batch.
For quality control purposes, PBL DNA integrity was evaluated
by agarose gel electrophoresis and spectrophotometry. DNAs
from FFPE samples were analysed by qPCR using the Infinium
FFPE QC kit (Illumina), and samples showing a delta-Ct value
below five were restored using the Infinium HD FFPE Restore kit
(Illumina), following the manufacturer’s instructions.
Quantity of 1000 ng PBL and 500 ng FFPE DNAs were bisulfite
converted using the EZ DNA Methylation Kit (Zymo Research),
according to the manufacturer’s instructions. To determine the
efficiency of the bisulfite conversion, a predetermined genomic
region was evaluated by Sanger sequencing in the methylated
and unmethylated controls and one sample from each batch.
Genome-wide methylation profiling was performed using the
Infinium Human Methylation 450 K Beadchip (Illumina), which
interrogates the methylation status of 485,764 CpG sites across
the genome. After hybridization, sample scanning was performed
using the HiScan platform (Illumina), which has a laser scanner
with two colors (532 nm/660 nm). The relative intensity of each
dye was analysed using GenomeStudio software (Methylation
Module). For each analysed CpG site, a β-value was obtained
depending on the florescence intensity. β measures took values
between 0 (unmethylated) and 1 (fully methylated). Analysis for
batch effects was performed using RnBeads software (Max-Planck-
Institut Informatik). Group comparisons and statistical analyses
(based on differentially methylated CpG sites, CpG islands,
promoters, genes and tiling) were also performed using RnBeads
software. CpG methylation was visualized by Integrative Genome
Viewer (Broad Institute). GRCh37/hg19 was used as the reference
genome.
The data discussed in this publication are accessible through
GEO Series accession number GSE107353 (https://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?acc = GSE107353).
Analysis of Alu elements. The sequence encompassing the MLH1-
EPM2AIP1 CpG island identified as the differentially methylated
region (DMR) in carriers of an MLH1 epimutation was screened for
repetitive elements by the RepeatMasker Web Server (Institute for
Systems Biology) using “Cross_match” as the search engine. No
repetitive elements were found in this DMR. Downstream of the
DMR, Alu elements were found in MLH1 intron 1, as previously
described24. The methylation status of these Alu elements was
tested in PBL DNA from three MLH1 epimutation carriers, one
healthy control and the RKO cell line by bisulfite sequencing of the
PCR fragments designated p24 (8 CpGs from Alu 2) and p25 (1
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CpG from Alu 3), as previously described24. Amplification of the
region p10 (control region, including 6 CpGs, unmethylated in
normal tissues and methylated in cancer tissues) was performed
using methylation-specific primers. Primers and conditions are
summarized in Table S3.
Mutational analyses
Screen of the EPM2AIP1-MLH1 CpG island for point mutations. The
EPM2AIP1-MLH1 CpG island is defined by its CpG content as the
region Chr3:37,034,229–37,035,355 by the UCSC genome browser
(CpG:93). Screening for promoter variants was performed by
amplification of two overlapping PCR fragments followed by direct
sequencing. Primers and PCR conditions are provided in Table S3.
Sequencing was performed using the BigDye Terminator v.3.1
Sequencing Kit (Applied Biosystems). Mutation Surveyor (Soft-
Genetics) was used for sequence visualization.
Detection of structural variants around the MLH1 locus. A screen
for the presence of structural alterations was performed on PBL
DNA from MLH1 epimutation carriers using a custom high-
definition CGH array designed with eArray Software (Agilent
Technologies) and manufactured by Agilent’s SurePrint oligo
technology. This comprised 15,000 probes encompassing the
MLH1 locus (region Chr3:36,450,000–37,900,000 within cytoband
3p22.2), with an average probe spacing of 100 bp intervals.
Bioinformatics analysis was performed in R using the 2.15.12
Bioconductor statistical packages. Results were visualized on
CytoGenomics Software (Agilent Technologies).
In silico functional evaluation of the genetic variants identified
PROMO 3.0 software25,26 was used to predict any changes in
transcription factor binding between wild-type alleles and
promoter variants. Only human transcription factors were
considered and 5% was selected as maximum matrix dissimilarity
rate.
Structural variants were compared with those previously
reported in the Database of Genomic Variants27, using chromo-
somal coordinates.
MLH1 allelic expression analyses
For allelic expression analyses at the MLH1 single-nucleotide
polymorphism (SNP) rs1799977 (c.655A>G), the relative levels of
the two alleles were determined in genomic DNA and cDNA by
single-nucleotide primer extension (SNuPE) as previously
described13 (see Supplementary Methods for details).
Haplotype analysis
Haplotype analysis was performed using four intragenic MLH1
SNPs rs1800734, rs9876116, rs1799977, and rs4234259, and seven
microsatellite markers, D3S1609, D3S1612, D3S2369, D3S1611,
D3S3623, D3S1298, and D3S3564, spanning 12 Mb around MLH1,
as previously described28. To deduce the methylation-associated
haplotype, intrafamilial segregation analysis was performed under
the assumption that the number of crossovers between adjacent
markers was minimal.
RESULTS
Validation of newly identified MLH1 epimutations and associated
functional impact
MLH1 promoter methylation was confirmed by MS-MLPA in blood
from newly identified epimutation carriers (Table 1). Three of them
presented methylation values higher than 40%, whereas case
CHN_2 displayed evidence of epigenetic mosaicism.
The frequent SNP rs1799977 (c.655G>A) within MLH1 exon 8
was used to determine the effect of the epimutation on the allelic
transcriptional activity of MLH1 in five carriers who were
heterozygous for this SNP. Monoallelic expression of the G allele
was identified in lymphocytes from case CHN_1, indicating
complete loss-of-expression from the epimutant A allele. In cases
CHN_2 and H12O-A, partial transcriptional silencing was observed
in lymphoblastoid cell lines derived from patient lymphocytes,
consistent with the observed methylation mosaicism (Table 1).
CHN_2 had reduced expression of the A allele with allele-specific
expression (ASE) 0.53, and H120-A had reduced expression of the
G allele, with ASE 0.79 (Table 1). Loss-of-expression of the
epimutant A allele was previously demonstrated in cases ICO_1
and M6013,23. The remaining cases were homozygotes for the
polymorphism, thus allelic expression analyses could not be
performed in them.
Genetic characterisation of the MLH1 locus
Since secondary constitutional MLH1 epimutations are linked to
rare variants or rearrangements involving the EPM2AIP1-MLH1
promoter, mutational analysis of the whole-CpG island encom-
passing the EPM2AIP1-MLH1 promoter was performed. The
common SNP rs1800734 (c.−93G>A) was identified in five of the
12 patients (42%) and rs34566456 (c.−593G>C) in case ICO_34.
Additionally, case HGUE_5 was heterozygous for a novel variant c.
−234_−236delCTT (Figure S1). In silico, this is located within the
binding region for the TFII-I and GATA-1 transcription factors, but
these were predicted to be unaffected by the variant. No other
variants, including c.[−27C>A; c.85G>T]3—were identified within
the MLH1 promoter region.
Screening for structural variants surrounding the MLH1 locus
(Chr3:36,450,000–37,900,000) identified three small deletions in
two of the 11 patients analysed, for whom sufficient DNA was
available (Figure S2, Table 1). Two deletions outside the
differentially methylated CpG island were identified in case
HGUE_2: one 15 Kb in size located upstream of the MLH1 gene
(Chr3:36,798,479–36,813,411) and the other of 19 Kb in size
located downstream (Chr3:37,486,324–37,505,162) (Figure S2A).
Neither of these two deletions has previously been described as
copy number variations in the DGV database (Table S4). In case
HGUE_1, a 20 Kb deletion was identified upstream of the MLH1
gene (Chr3:36,396,587–36,416,879) (Figure S4B). This region
appears to be prone to copy number variations in the control
reference group (DGV database), as shown in Table S4. In both
cases (HGUE_1 and HGUE_2), validation of these deletions using a
second method was not possible due to sample depletion.
Determination of the methylation-associated allele (MAA)
Clonal bisulfite sequencing was performed on PBL DNA of
probands harboring a heterozygous variant within the MLH1
promoter region to determine the MAA. Dense monoallelic MLH1
methylation was linked to the G allele at SNP rs1800734 (c.
−93G>A) in cases H12O-A and HGUE_2, and to the allele A in
patients CHN_1 and HGUE_5 (Table 1). In case HGUE_5, who was
heterozygous for both the novel heterozygous variant c.−234_
−236del and the c.−93G>A SNP, methylation was linked to the
non-deleted and c.−93A alleles, and the [c.−234_−236del; c.−93G]
haplotype was unmethylated (Figure S3). This finding indicated
the c.−234_−236del variant was not causally linked to the
epimutation in HGUE_5. In patient ICO_34, methylation was
linked to the G allele at SNP rs34566456 (c.−593G>C) with ~38% of
G alleles methylated, indicating mosaicism (Table 1), consistent
our prior findings using other methods13.
Inheritance pattern of the epimutant alleles and designation of
MLH1 epimutation as likely primary or secondary
To investigate the inheritance pattern of the genetic allele
harboring the epimutation, the MLH1 promoter methylation status
and haplotypes within a 12 Mb around MLH1 were determined in
available PBL DNA from the first-degree relatives of epimutation
carriers (Table S5). MS-MLPA analysis showed no evidence of
MLH1 methylation in any of the relatives tested from any family,
MLH1 epimutation is a focal epigenetic event
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thus no case of transmission of an epimutation was observed
among the family members tested (Figs. 1, 2). Haplotype analyses
revealed that the genetic allele bearing the epimutation (in the
proband) was shared in unmethylated form by two sisters of case
ICO_34, suggesting a de novo occurrence of the epimutation in
proband ICO_34; one sister and two offspring of case CHN_1,
suggesting de novo occurrence of the epimutation in proband
CHN_1 and indicating inter-generational erasure of the epimuta-
tion in her offspring (Fig. 1). The inter-generational erasure newly
observed in case CHN_1 herein, and previously observed in case
ICO_113, allowed us to definitively classify the epimutation in
these two cases as primary. In six additional cases, the absence of
methylation in the relatives tested, and/or the lack of a family
history of cancer, also suggested their epimutation was of the
primary type.
In patient HGUE_2, although clonal bisulphite sequencing
showed monoallelic methylation of the c.−93A allele, we were
unable to determine whether this was linked in-cis to either or
both of the 15 Kb and 19 Kb deletions flanking MLH1 that were
also identified in this patient. The MAA was not transmitted to
either of his offspring, hence this family was non-informative for
whether the type of epimutation carried by this proband was
primary or secondary. Similarly, in case HGUE_1, we were unable
to determine whether the epimutation was linked in-cis to the 20
Kb deletion identified upstream of MLH1, hence whether the
deletion may have been causally related.
Global epigenetic characterisation of MLH1 constitutional
epimutations
In order to evaluate whether aberrant methylation was restricted
to MLH1 or extended to other loci across the genome in MLH1
epimutation carriers, methylation array analysis was performed
using the Infinium 450 k array in PBL DNA. This revealed that the
MLH1-EPM2AIP1 promoter CpG island was the sole differentially
methylated region (DMR) in MLH1 epimutation carriers when
compared to healthy controls (false discovery rate (FDR) adjusted
p-value = 2.45E−42) (Fig. 3a). The same result was obtained when
MLH1 epimutation carriers were compared to LS cases (FDR
adjusted p-value = 3.45E−61) (Fig. 3b), and the subset of LS cases
with germline MLH1 mutation (FDR adjusted p-value = 6.41E−21)
(Fig. 3c). Accordingly, the same analysis identified MLH1 and
EPM2AIP1 as the unique differentially methylated promoters in
MLH1 epimutation carriers compared to healthy controls
(EPM2AIP1 FDR adjusted p-value = 2.21E−43, MLH1 FDR adjusted
p-value = 2.19E−35), LS patients (EPM2AIP1 FDR adjusted p-value
= 5.07E−61, MLH1 FDR adjusted p-value = 9.23E−51), and MLH1-
mutated LS cases (EPM2AIP1 FDR adjusted p-value = 8.41E−21,
MLH1 FDR adjusted p-value = 1.51E−16) (Fig. 3).
A deeper analysis at the MLH1 promoter region showed that the
methylation levels in PBL from constitutional epimutation carriers
spread across the entire CpG island, MLH1 exon1 and the first part
of intron 1 (Fig. 4). The CpG island shores were also affected by
hypermethylation, represented by probes at positions chr3:
37,033,791 and chr3: 37,035,400 at the boundaries of the 1.6 Kb
DMR. Of note, no other common DMR were found in the genome-
wide methylation analysis among the carriers of a MLH1
constitutional epimutation.
The DMR identified in the PBL of MLH1 epimutation carriers was
also present in subject-matched normal colonic mucosa and
colorectal cancer (CRC) (when available for analysis). Although
methylation levels across the DMR were marginally higher in CRC



































































Fig. 1 Pedigrees of the MLH1 epimutation cases showing that the presence of the epimutation does not co-segregate with any genetic allele.
Circles, females; squares, males; filled, cancer affected. Cancer localization (CRC, colorectal cancer; OC, ovarian cancer; EC, endometrial cancer;
BC, breast cancer; Lk, leukaemia; BrC, brain cancer; PC, prostate cancer) and age at diagnosis are indicated. Epimutation carriers are indicated
by an arrow. Generations are indicated on the left margin in Roman numerals and analysed relatives are identified by numbers. Haplotypes
are schematised by sticks: Red=methylation-associated allele (MAA), Black= haplotype also carried by the proband but not associated with
the epimutation, Blue= un-informative haplotypes. The presence of methylation (M) or its absence (UM) is indicated on the red MAA
haplotypes for those individuals tested)
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significance, suggesting that methylation is not a common second
hit in these tumors (Fig. 5a). Similarly, no significant differences
were found in the levels of methylation among the tissues tested
from mutation-positive LS cases (Fig. 5b).
In normal colonic mucosa tissue, a lack of MLH1 methylation
was similarly observed in the LS control group and the sporadic
cases with somatic MLH1 methylation in their tumors (Figure S3A).
By contrast, in tumor tissue, the sporadic MLH1-methylated CRC
cases showed a more extensive DMR spanning ≈50 Kb (from
chr3:36,985,516 to chr3:37,035,399), within which four CpG sites
located at chr3:36,986,513; 36,986,532; 36,986,555, and 36,986,642
were differentially methylated only in the sporadic CRC (FDR
adjusted p-value <0.01) (Figure S3B and S3C).
Methylation state of Alu elements
In order to evaluate whether demethylation of MLH1 intron 1 Alu
sequences is associated with constitutional epimutation, as has
been suggested for sporadic MSI tumors24, bisulfite sequencing
analysis was performed in PBL DNA from 3 MLH1 epimutation
carriers (cases ICO_1, ICO_34, and CHN_1), one healthy control
and the RKO cell line. As previously described, partial demethyla-
tion was observed in Alu 3 of RKO cells (Figure S4). By contrast, the
intron 1 Alu CpGs analysed were found to be fully methylated in
carriers of a constitutional MLH1 epimutation and a healthy
control (Figure S4), arguing against demethylation of these nearby
Alu sequences as a causal mechanism for constitutional
epimutation.
DISCUSSION
A comprehensive genetic and epigenetic analysis has provided a
deeper and broader molecular characterisation of 12 cases with
constitutional MLH1 epimutation than previously undertaken. The




























































































Fig. 2 Pedigrees of the MLH1 epimutation carriers not included in Fig. 1.Circles, females; squares, males; filled, cancer affected. Cancer
localization (CRC, colorectal cancer; BC, breast cancer; Lk, leukaemia; BrC, brain cancer; PC, prostate cancer; SkC, skin cancer; GC, gastric cancer;
OrC, oral cancer; BC, breast cancer; PaC, pancreatic cancer; NC, neck cancer) and age at diagnosis are indicated. Epimutation carriers are
indicated by an arrow. Generations are indicated on the left margin in Roman numerals and analysed relatives are identified by numbers. The
presence of methylation (M) or its absence (UM) is indicated if tested
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cases of constitutional MLH1 epimutation reported to date
(Table S6). Our findings suggest that the epimutations in at least
10 of these cases are primary based on the following: (i) the
absence of rare in-cis genetic aberrations within the MLH1 CpG
island, (ii) the lack of familial cancer history and the presence of
the MAA in an unmethylated state in siblings and/or parents that
point to a de novo occurrence of the epimutation in the probands
(Table S1 and S5); and (iii) the demonstration in two cases of the
inter-generational erasure of the epimutation in offspring who
inherited the MAA. Interestingly, few studies of MLH1 epimutation
that have involved family members from more than one
generation have ever been undertaken, but among these, both
inter-generational inheritance and erasure of the epimutation
between the proband and offspring have been described
Constitutional MLH1 epimutation carriers vs. Healthy controls
Constitutional MLH1 epimutation carriers vs. mutation-positive Lynch syndrome patients
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Fig. 3 Scatterplot of the normalized mean β-values obtained using the Infinium 450 k Human Methylation array to identify differentially
methylated CpG islands and promoters in blood DNA from constitutional MLH1 epimutation carriers against healthy controls a and Lynch
syndrome patients with a germline sequence mutation b. The transparency corresponds to point density. One % of the points in the sparsest
populated plot regions are drawn explicitly. The colored points represent differentially methylated CpG islands (depicted as arrow #1) and
promoters (arrows #2 and #3). FDR adjusted p-values of differentially methylated regions are summarized at the bottom c.
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(Table S5). The two cases of inter-generational erasure, we
describe herein provide further evidence of the reversibility of
this defect between generations (Table S5, Fig. 1).
In two cases, HGUE_1 and HGUE_2, deletions external to MLH1
were identified by aCGH. However, we were unable to confirm the
presence of these deletions by other methods due to the lack of
sample availability. Also, we could not determine whether the
deletions occurred on the MAA. Noteworthy, secondary MLH1
epimutations have been reported with concomitant genetic
alterations in-cis, including promoter deletions, a promoter
single-nucleotide variant, and a large duplication encompassing
MLH1 and neighboring genes3–10,29. These cases have displayed
autosomal dominant inheritance of the MLH1 epimutation with
faithful segregation of the methylation with the genetic alteration.
Therefore, although we cannot completely rule out that deletions
are causative of the epimutation in cases HGUE_1 and HGUE_2,
the absence of family history and methylation in blood from first-
degree relatives, led us to propose to classify them as “suspected
primary” (Table S6).
Transcriptional silencing usually correlates with methylation
levels (Table S6). In case H12O-A, differences in the values of
methylation and transcriptional silencing could be found depend-
ing upon the sample tested. The lymphoblastoid cell line
displayed less methylation than that observed in blood, in line
with a previous observation30. These results highlight the
limitations of using lymphoblastoid cell lines for epigenetic-
based analyses, although this may be a necessity when primary
tissue samples from patients are limited.
The array-based genome-wide methylation analysis performed
in PBL DNA demonstrated that a region of 1.6 Kb
(Chr3:37,033,791–37,035,400)—encompassing the shared MLH1-
EPM2AIP1 CpG island and its corresponding shores- was the sole
DMR unique to the group of MLH1 epimutation carriers, as
compared to mutation-positive LS patients or healthy controls. For
cases HGUE_1 and HGUE_2, classified as suspected primary
epimutations the same 1.6 Kb DMR was identified. No differences
in the length of the DMR were observed in the normal colon
mucosa or CRC tissue among the MLH1 epimutation carriers.
The absence of any other DMR in the MLH1 epimutation carrier
group suggests that the constitutional epimutation is caused by a
shared focal event, since it spans the very same region in all
patients tested. Of note, our preliminary analysis does not suggest
a genetic cause. Also, we have provided evidence against MLH1
intron 1 Alu sequence demethylation as a causal mechanism for
constitutional MLH1 epimutation.
Interestingly, the extent of the DMR observed (consistently in all
three tissue types analysed) in MLH1 epimutation carriers was
narrower than that the observed in sporadic MLH1-methylated
CRC. Although our cases of sporadic MLH1-methylated CRC were
few (n = 4), the extent of their methylation (50 Kb) is consistent
with tumors with available MSI and methylation data from TCGA
project (n = 43) (Figure S5).
While the causal mechanism of primary constitutional MLH1
epimutations remains unknown, it may be speculated that it acts in
the very early stages of embryonic development2. MLH1 de novo
methylation has been induced in vitro in human embryonic stem
cells suggesting that pluripotency is a mandatory requirement for
establishing the epimutation31. The detection of non-methylated
clones on the MAA in distinct patients, including those with
methylation levels close to 50% (Table S5), suggests that if an
epimutation is established in the germline, some alleles may lose the
methylation during the demethylation phase that occurs between
zygote formation and the preimplantation embryogenesis2. The
methylated allele could behave as a “leaky” allele when self-
propagating the MLH1 epimutation within individual cells.
Our results show that aberrant methylation of the MLH1
promoter is targeted, as opposed to disseminated, since we























































































































































































































































































































































































































































































































































































CHROMOSOME 3 COORDINATE (GRCH37/HG19)
Epimutation carriers (n = 11) Healthy individuals (n = 41) Mutation-positive Lynch syndrome patients (n = 51)
MLH1EPM2AIP1 LRRFIP2




Fig. 4 Representation of the differentially methylated region across the MLH1 locus in blood DNA from constitutional MLH1 epimutation
carriers (red, n= 11), Lynch syndrome mutation carriers (green, n= 61) and healthy controls (black, n= 41).β-values obtained from Infinium
450 k Human Methylation array analysis are displayed against the genomic coordinate for each CpG site interrogated. The relative locations of
the CpG sites are not drawn to scale. CpG sites located between Chr3:37,033,791–37,035,399 coordinates had FDR adjusted p-values between
2.5E−7 and 1.2E−59 for comparisons of MLH1 epimutation carriers against Lynch syndrome patients or healthy controls. Above, CpG islands
(CI) are represented as black rectangles and their shores are represented in grey. Location of Deng’s promoter regions (DR) is indicated as
white rectangles A–D. Genes (G) containing the displayed CpG sites are represented as grey rectangles. Ensembl GRCh37 was taken as
reference for gene coordinates
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carriers. This suggests that a primary epimutation is not derived
from a trans-event or a cellular perturbation during germline or
embryonic development. Further studies are needed to fully
understand the mechanistic basis of MLH1 constitutional epimuta-
tions and their heritability/reversibility. Ongoing mechanistic
studies should be focused on specific interactions of epigenetic
effectors with the MLH1 locus, paying special attention to those
acting in the germline or during early embryonic development.
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